Report September 2009

Status Report, ICP Project

Diagnostic Kits

General Status

• He have created a glossary of research vocabulary that has a allowed us to better define the field.
• We have developed a bibliography with literary reviews of the key articles.
  • We have found that genetic diagnostic kits are probably best suited for this study
• We are developing a better understanding of the intellectual property landscape and have established that a wide variety of protections are used including: patent, trade secrets, NDAs, Non-compete, non-solicitation, confidentiality agreements. Economics of IP & IP
  • Patents
    • There has been "an increase in patents on the inputs to drug discovery (“research tools”)." (Cohen et. al., 2003)
      • no substantially barriers have been found as a result of this increase in patents on the inputs to drug discovery (Cohen et. al., 2003)
      • no substantially barriers found to university research (Cohen et. al., 2003)
      • THE EXCEPTION: "Restrictions on the use of patented genetic diagnostics, where we see some evidence of patents interfering with university research, are an important exception. There is, also, some evidence of delays associated with negotiating access to patented research tools, and there are areas in which patents over targets limit access and where access to foundational discoveries can be restricted. There are also cases in which research is redirected to areas with more intellectual property (IP) freedom. Still, the vast majority of respondents say that there are no cases in which valuable research projects were stopped because of IP problems relating to research inputs." (Cohen et. al., 2003)
    • The perception of rising patent litigation rates in the area of DNA-based patents is most likely false (Mills, A.E. & Tereskerz, P., 2008)
  • Licenses
    • Four licensing approaches: (Geertrui Van Overwalle et al., 2005)
      • Free access to the genetic sequences but royalty payments for the commercial test kits
      • Licensing to laboratories at a rate that makes the commercial test kit more economical
      • Exclusively licensing to a limited number of laboratories
      • Biological Innovation for Open Society license that makes improvements to the patent shared as a way to facilitate cooperative invention.

• No open business models have emerged in the literature or through interviews.
• We recently addresses the organizational needs of the paper in a few ways
  • We added a new Diagnostic Kits section called Structured_Rational_for_the_Paper
    • This section includes:
      • The Argument Framework
      • Bibliographic Needs
  • More importantly the heading for the Bibliography is now a link to a page that organizes the Bibliography according to the papers argument framework.

Work Completed

• Bibliography with Literature Review
• Glossary (v.1)

Work Partially Completed

• Overview of Economics of Intellectual Property in Kits
• IP in Kits
• IP Profile of Universities working in Kits
• Commons based cases in Kits
• Interviews with experts on diagnostic kits

Work Remaining

• Give an overall picture of the Kits' sector
• Data, narratives and tools produced by the Kits' sector
• Competitive advantages in Kits
• IP Profile of Biggest for-profit companies in Kits
• IP Profile of non-profit companies in Kits
• IP Profile of Associations in Kits
• Peer-Production Business models in Kits
• Open Business models in Kits

Research Methodology in use

• Case studies
• Literature review
• Industry analysis
• Business reports and press releases
• University reports and press releases

Problems and Considerations

• How can we learn more about the use of trade secret protection of data?
• What information should we aim to obtain through interviews?
• Should we focus on genetic diagnostic tests exclusively?

Next Steps

• Continue to add information to the research methodology. Specifically, increase information about University contributions.
• Continue to interview experts in the field